Privia Health Group (NASDAQ:PRVA) CEO Sells $586,109.70 in Stock

Privia Health Group, Inc. (NASDAQ:PRVA) CEO Parth Mehrotra sold 26,763 shares of Privia Health Group stock in a transaction on Thursday, March 12th. The stock was sold at an average price of $21.90, for a total transaction of $586,109.70. Following the completion of the transaction, the chief executive officer directly owned 609,181 shares of the company’s stock, valued at $13,341,063.90. The trade was a 4.21% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Parth Mehrotra also recently made the following trade(s):

• On Monday, March 16th, Parth Mehrotra sold 26,509 shares of Privia Health Group stock. The shares were sold at an average price of $22.11, for a total transaction of $586,113.99.
• On Friday, March 13th, Parth Mehrotra sold 27,229 shares of Privia Health Group stock. The shares were sold at an average price of $21.52, for a total transaction of $585,968.08.
• On Tuesday, March 10th, Parth Mehrotra sold 21,097 shares of Privia Health Group stock. The stock was sold at an average price of $22.71, for a total value of $479,112.87.
• On Monday, March 9th, Parth Mehrotra sold 41,999 shares of Privia Health Group stock. The stock was sold at an average price of $22.86, for a total value of $960,097.14.
• On Friday, March 6th, Parth Mehrotra sold 21,440 shares of Privia Health Group stock. The shares were sold at an average price of $23.15, for a total value of $496,336.00.

Privia Health Group Price Performance

Shares of PRVA stock opened at $21.59 on Thursday. The company has a market cap of $2.67 billion, a PE ratio of 127.00, a price-to-earnings-growth ratio of 1.39 and a beta of 0.82. Privia Health Group, Inc. has a 1 year low of $18.77 and a 1 year high of $26.51. The stock’s 50 day simple moving average is $22.75 and its two-hundred day simple moving average is $23.60.

Privia Health Group (NASDAQ:PRVA) last announced its earnings results on Thursday, February 26th. The company reported $0.25 EPS for the quarter, topping analysts’ consensus estimates of $0.04 by $0.21. Privia Health Group had a return on equity of 3.06% and a net margin of 1.08%.The firm had revenue of $541.17 million during the quarter, compared to analysts’ expectations of $516.61 million. During the same quarter in the previous year, the business earned $0.21 EPS. The company’s quarterly revenue was up 17.4% on a year-over-year basis. Equities research analysts expect that Privia Health Group, Inc. will post 0.14 EPS for the current year.

Analyst Ratings Changes

A number of research firms have weighed in on PRVA. Truist Financial boosted their price objective on shares of Privia Health Group from $31.00 to $33.00 and gave the company a “buy” rating in a research report on Monday, March 2nd. Stephens reaffirmed an “overweight” rating and set a $32.00 price target on shares of Privia Health Group in a research note on Thursday, December 4th. Royal Bank Of Canada assumed coverage on shares of Privia Health Group in a report on Friday, January 9th. They set an “outperform” rating and a $31.00 price target on the stock. Piper Sandler reissued an “overweight” rating and issued a $36.00 price objective on shares of Privia Health Group in a research report on Thursday, February 26th. Finally, Canaccord Genuity Group raised their price objective on shares of Privia Health Group from $34.00 to $35.00 and gave the stock a “buy” rating in a research note on Friday, February 27th. Thirteen research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $31.00.

Institutional Trading of Privia Health Group

Institutional investors and hedge funds have recently made changes to their positions in the business. Bayban bought a new position in shares of Privia Health Group in the fourth quarter worth about $26,000. Invesco Ltd. lifted its holdings in Privia Health Group by 5.1% during the 4th quarter. Invesco Ltd. now owns 427,615 shares of the company’s stock valued at $10,139,000 after buying an additional 20,652 shares in the last quarter. Wellington Management Group LLP boosted its position in Privia Health Group by 3.8% in the 4th quarter. Wellington Management Group LLP now owns 233,446 shares of the company’s stock valued at $5,535,000 after buying an additional 8,531 shares during the period. Millennium Management LLC boosted its position in Privia Health Group by 19.0% in the 4th quarter. Millennium Management LLC now owns 702,744 shares of the company’s stock valued at $16,662,000 after buying an additional 112,428 shares during the period. Finally, Gotham Asset Management LLC grew its stake in Privia Health Group by 22.4% in the 4th quarter. Gotham Asset Management LLC now owns 36,995 shares of the company’s stock worth $877,000 after acquiring an additional 6,773 shares in the last quarter. 94.48% of the stock is currently owned by institutional investors.

Privia Health Group Company Profile

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.